Gosset Ownership
Private
Employees
~5
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
MetiMedi Pharmaceuticals General Information
Phase 2 trial of OMT‑111/METI‑101 for refractory metastatic colorectal cancer has been successfully processed with the last patient under investigation. The company plans to report results to Korean authorities after analysis. Early data suggest efficacy and safety.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Uiwang-si, Gyeonggi-do
South Korea
South Korea
Drug Pipeline
OMT-111
Phase 2Key Partnerships
MetiMedi Pharmaceuticals Funding
No funding data available
To view MetiMedi Pharmaceuticals's complete valuation and funding history, request access »